Table 3

Key safety outcomes

Baseline12 months
BCVA LogMAR, mean (Snellen equivalent)0.81 (20/130)0.26 (20/36)
IOP, mm Hg, mean±SD24.2±6.914.6±3.2
IOP >30 mm Hg, %100
IOP>20 mm Hg, %700
>2 lines drop in BCVA0%
IOP-lowering drugs, mean, n1.30.5
Endothelial cell density, cells/mm2, mean±SD2619±2282312±210
ECD <2000 cells/mm2, n00
0
>25% endothelial cell loss, n0
Inflammation, persistent (>1M)0
Inflammation, severe (grade 4+)0
Hyphema, persistent (>1M)0
Hyphema, severe (>3 mm)0
Corneal oedema, persistent (>1M)0
Stent migration0
Stent-corneal touch0
  • BCVA, Best Corrected Visual Acuity; ECD, Endothelial Cell Density; IOP, intraocular pressure.